Q & A

Pediatric Infectious Disease Journal

Volumn 24, Issue 11 SUPPL., 2005, Pages

  Mejías, Asunción ^a   Chávez Bueno, Susana ^a   Jafri, Hasan S ^a   Ramilo, Octavio ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDI 524; MONOCLONAL ANTIBODY MEDI 524; NUMAX; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHIOLITIS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; NOTE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS LOAD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; MOUSE; MUCUS SECRETION; PLETHYSMOGRAPHY; PNEUMONIA; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; ADULT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; IMMUNOLOGY; INFANT; NEWBORN; PATHOGENICITY; PATHOPHYSIOLOGY; PREMATURITY; REVIEW; VIRAL BRONCHIOLITIS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHIOLITIS, VIRAL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 33644819940     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000188196.87969.9a     Document Type: Article

References (25)

1. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004;22:275-284.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-1759.
3. Respiratory syncytial virus activity: United States, 2003-2004. MMWR. 2004;53:1159-1160.
4. Mejias A, Chavez-Bueno S, Sanchez PJ. Respiratory syncytial virus prophylaxis. Neoreviews. 2005;6:e26-e31.
5. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis. 2004;189:1856-1865.
6. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-545.
7. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137-141.
8. Mejias A, Chavez-Bueno S, Rios AM, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother. 2004;48:1811-1822.
9. Mejias A, Chavez-Bueno S, Rios AM, et al. Asthma and respiratory syncytial virus: new opportunities for therapeutic intervention. An Pediatr (Barc). 2004;61:252-260.
10. Anonymous. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
11. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
12. DeVincenzo JP, Hall CB, Kimberlin DW, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis®)-resistant mutants. J Infect Dis. 2004;190:975-978.
13. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350:126-144.
14. Mejías A, Chavez-Bueno S, Rios AM, et al. Comparative effect of an anti-respiratory syncytial virus monoclonal antibodies on viral replication and disease severity in the RSV murine model. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; November 1, 2004, Washington, DC.
15. Simoes EA, Carbonell-Estrany X, Kimpen, J, et al. Palivizumab use decreases risk of recurrent wheezing in preterm children. In: 14th European Respiratory Society Annual Congress, Glasgow, Scotland, 2004. [Abstract 1349]
16. Guerrero-Plata A, Ortega E, Ortiz-Navarrete V, Gomez B. Antigen presentation by a macrophage-like cell line persistently infected with respiratory syncytial virus. Virus Res. 2004;99:95-100.
17. Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med. 2004;169:801-805.
18. Chavez-Bueno S, Mejias A, Gomez AM, et al. Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model. Virol J. 2005;2:46.
19. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618-1623.
20. Tripp RA. The brume surrounding respiratory syncytial virus persistence. Am J Respir Crit Care Med. 2004;169:778-779.
21. Gill MA, Connolly JE, Xue Y, Bhuta V, Ramilo O, Banchereau J. Respiratory syncytial virus blocks antigen presentation by human dendritic cells. In: Pediatric Academic Societies' Annual Meeting, 2005, Washington, DC. [Abstract 1586]
22. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422-434.
23. Englund J. In search of a vaccine for respiratory syncytial virus: the saga continues. J Infect Dis. 2005;191:1036-1039.
24. Tang RS, MacPhail M, Schickli JH, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol. 2004;78:11198-11207.
25. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191:1093-1094.